StockDrifts LogoStockDrifts

Hans Biomed 042520

Company
한스바이오메드Hans Biomed
Insiders
2
Buys
0
Total Value
₩896M ($622K)
Avg Return
-140.13%
Last Filing
2026-01-19

Hans Biomed (042520) has 0 disclosed insider purchases and 2 disclosed disposals on record, filed by 2 distinct insiders. Together those filings cover ₩896M ($622K) in reported transaction value. The earliest filing StockDrifts holds for Hans Biomed is dated 2023-03-30; the most recent is 2026-01-19.

Price & insider activity (12 months)

Recent insider trades

DateTypeSourceInsiderPositionSharesPrice at filingReturnValue
2026-01-19BUY주식매수선택권
문대희
Daehee Moon
moving5.0K₩22,650+100.0%₩113M ($79K)
2025-10-27SELLMarket Sell
오상석
Sangseok Oh
Outside Director-1.6K₩33,300-36.0%₩54M ($38K)
2025-09-26SELLMarket Sell
오스템임플란트
Osstem Implant
--64.0K₩13,160-244.2%₩842M ($585K)
2025-01-01BUY신규선임
문대희
Daehee Moon
moving2.5K₩9,060+400.0%₩23M ($16K)
2023-03-30BUY전환사채의권리행사
오스템임플란트
Osstem Implant
-1.4M₩15,270+196.7%₩21.5B ($14.9M)

Frequently asked questions

Who has been buying Hans Biomed stock?
2 distinct insiders have filed 0 disclosed insider purchases in Hans Biomed (042520), most recently on 2026-01-19. Each filer, their role, the number of shares and the price at filing are listed in the table on this page.
How many insider filings does Hans Biomed have?
Hans Biomed has 0 buy-side and 2 sell-side disclosures on record, covering ₩896M ($622K) in total reported value, spanning 2023-03-30 to 2026-01-19.
Do insider buys in Korean stocks predict returns?
Not uniformly. StockDrifts analysed 170,720 share-count changes across 56,930 Korean regulatory filings using cross-sectional alpha at fixed forward horizons, and found returns concentrated in particular signal tiers rather than in insider buying generally.

More on this data

Every trade listed above comes from an official regulatory disclosure. For how StockDrifts scores these disclosures, see the Korea insider signal tier research, or browse every Korean stock we track.